PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
December 8, 1998CirculationOpen Access

Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does pravastatin reduce recurrent coronary events in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels?

Population

4,139 myocardial infarction survivors with average cholesterol levels, including 586 with clinical diagnoses…

Comparison

Pravastatin vs Placebo

Design

RCT

Follow-up

5 years

Authors

RGRonald GoldbergMMMargot J. MelliesFSFrank M. Sacks

Discussion

Loading...

Member takes

Overview

Supports pravastatin in post-MI diabetics with average cholesterol; extends secondary prevention evidence to this high-risk subgroup.

Structured PICO

Does pravastatin reduce recurrent coronary events in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels?

P
Population
4,139 myocardial infarction survivors with average cholesterol levels, including 586 with clinical diagnoses of diabetes and 342 with impaired fasting glucose.
I
Intervention
Pravastatin
C
Comparator
Placebo
O
Outcome
Recurrent coronary events (composite of CHD death, nonfatal myocardial infarction [MI], CABG, and PTCA)composite

Pravastatin significantly reduces the risk of recurrent coronary events in post-myocardial infarction patients with diabetes or impaired fasting glucose who have average cholesterol levels.

Cite This Study

Goldberg et al. (1998) studied this question.

synapsesocial.com/papers/6a0e16927a57fdc4e227a3aehttps://doi.org/10.1161/01.cir.98.23.2513
View Full Paper
Ask AI
Bookmark
Share